Should You Buy Intelligent Bio Solutions Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Intelligent Bio Solutions Inc. (INBS) scores 5.4/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $1.81, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 11 of 11 CirclFi valuation models project upside for Intelligent Bio Solutions Inc. (INBS) at $1.81 — the model consensus leans bullish, with a Quality Score of 5.4/10 and Value-Trap risk of 33/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $6.06 (+234.6% upside)
- According to the CirclFi Deep Alpha Valuation Engine, 10 of 11 models identify upside from $1.81 to a composite fair value of $4.25, indicating the market hasn't fully priced in Intelligent Bio Solutions Inc.'s earnings power.
- According to the CirclFi Deep Alpha Valuation Engine, the FTNN Topology model targets a fair value of $6.06 (+234.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
The Bear Case
No active models currently flag significant downside for INBS. However, the Value Trap score of 33/100 introduces some caution.
The Bottom Line
The convergence of 5.4/10 quality, multi-model undervaluation (10/11 bullish, +134.7% avg. upside), and a composite fair value of $4.25 vs. $1.81 current price makes Intelligent Bio Solutions Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Intelligent Bio Solutions Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy INBS stock right now?
Based on CirclFi's multi-model analysis, 11 of 11 models see upside for INBS at $1.81. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.4/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Intelligent Bio Solutions Inc.?
Key risks include: wide model disagreement (224% spread), signaling high uncertainty; general market and sector-specific risks affecting Surgical & Medical Instruments & Apparatus companies. Always diversify and consult a financial advisor.
How does INBS compare to its competitors?
Among Surgical & Medical Instruments & Apparatus peers, INBS holds a Quality Score of 5.4/10. Comparable companies include DXCM (QOC 10.0), IRMD (QOC 10.0), PODD (QOC 10.0). The relative ranking helps investors identify whether INBS offers better fundamental quality than alternatives in the same sector.
Is INBS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. INBS's Quality Score of 5.4/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy INBS at?
CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $1.87 to $6.06. At $1.81, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for INBS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad